390 related articles for article (PubMed ID: 17003518)
41. The immunology of pregnancy: regulatory T cells control maternal immune tolerance toward the fetus.
La Rocca C; Carbone F; Longobardi S; Matarese G
Immunol Lett; 2014 Nov; 162(1 Pt A):41-8. PubMed ID: 24996040
[TBL] [Abstract][Full Text] [Related]
42. Few Foxp3⁺ regulatory T cells are sufficient to protect adult mice from lethal autoimmunity.
Mayer CT; Ghorbani P; Kühl AA; Stüve P; Hegemann M; Berod L; Gershwin ME; Sparwasser T
Eur J Immunol; 2014 Oct; 44(10):2990-3002. PubMed ID: 25042334
[TBL] [Abstract][Full Text] [Related]
43. [Regulatory T lymphocytes CD4(+): current issues].
Siri A; de Boysson H; Boursier G
Med Sci (Paris); 2012; 28(6-7):646-51. PubMed ID: 22805142
[TBL] [Abstract][Full Text] [Related]
44. Advances on Non-CD4 + Foxp3+ T Regulatory Cells: CD8+, Type 1, and Double Negative T Regulatory Cells in Organ Transplantation.
Ligocki AJ; Niederkorn JY
Transplantation; 2015 Aug; 99(8):1553-9. PubMed ID: 26193065
[TBL] [Abstract][Full Text] [Related]
45. Regulatory T cells and tolerogenic dendritic cells: from basic biology to clinical applications.
Rutella S; Lemoli RM
Immunol Lett; 2004 Jun; 94(1-2):11-26. PubMed ID: 15234530
[TBL] [Abstract][Full Text] [Related]
46. The CII-specific autoimmune T-cell response develops in the presence of FTY720 but is regulated by enhanced Treg cells that inhibit the development of autoimmune arthritis.
Miller DC; Whittington KB; Brand DD; Hasty KA; Rosloniec EF
Arthritis Res Ther; 2016 Jan; 18():8. PubMed ID: 26757712
[TBL] [Abstract][Full Text] [Related]
47. Type 1 diabetes vaccine candidates promote human Foxp3(+)Treg induction in humanized mice.
Serr I; Fürst RW; Achenbach P; Scherm MG; Gökmen F; Haupt F; Sedlmeier EM; Knopff A; Shultz L; Willis RA; Ziegler AG; Daniel C
Nat Commun; 2016 Mar; 7():10991. PubMed ID: 26975663
[TBL] [Abstract][Full Text] [Related]
48. Advances in the Study of CD8+ Regulatory T Cells.
Tang X; Kumar V
Crit Rev Immunol; 2019; 39(6):409-421. PubMed ID: 32421955
[TBL] [Abstract][Full Text] [Related]
49. Circulating subsets and CD4(+)CD25(+) regulatory T cell function in chronic inflammatory demyelinating polyradiculoneuropathy.
Sanvito L; Makowska A; Gregson N; Nemni R; Hughes RA
Autoimmunity; 2009; 42(8):667-77. PubMed ID: 19886739
[TBL] [Abstract][Full Text] [Related]
50. Induction of dominant tolerance using monoclonal antibodies.
Agua-Doce A; Graça L
Methods Mol Biol; 2007; 380():405-29. PubMed ID: 17876109
[TBL] [Abstract][Full Text] [Related]
51. Molecular mechanisms of regulatory T cell development and suppressive function.
Kim JM
Prog Mol Biol Transl Sci; 2010; 92():279-314. PubMed ID: 20800825
[TBL] [Abstract][Full Text] [Related]
52. Double-negative regulatory T cells induce allotolerance when expanded after allogeneic haematopoietic stem cell transplantation.
McIver Z; Serio B; Dunbar A; O'Keefe CL; Powers J; Wlodarski M; Jin T; Sobecks R; Bolwell B; Maciejewski JP
Br J Haematol; 2008 Apr; 141(2):170-8. PubMed ID: 18318770
[TBL] [Abstract][Full Text] [Related]
53. Transforming growth factor-beta: an important role in CD4+CD25+ regulatory T cells and immune tolerance.
Zhang L; Yi H; Xia XP; Zhao Y
Autoimmunity; 2006 Jun; 39(4):269-76. PubMed ID: 16891215
[TBL] [Abstract][Full Text] [Related]
54. Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells.
Khan S; Burt DJ; Ralph C; Thistlethwaite FC; Hawkins RE; Elkord E
Clin Immunol; 2011 Jan; 138(1):85-96. PubMed ID: 21056008
[TBL] [Abstract][Full Text] [Related]
55. Nanoparticle-based autoimmune disease therapy.
Serra P; Santamaria P
Clin Immunol; 2015 Sep; 160(1):3-13. PubMed ID: 25704658
[TBL] [Abstract][Full Text] [Related]
56. Regulatory T cells as central regulators of both autoimmunity and B cell malignancy in New Zealand Black mice.
Scaglione BJ; Salerno E; Gala K; Pan M; Langer JA; Mostowski HS; Bauer S; Marti G; Li Y; Tsiagbe VK; Raveche ES
J Autoimmun; 2009 Feb; 32(1):14-23. PubMed ID: 19022624
[TBL] [Abstract][Full Text] [Related]
57. The chromatin-modifying enzyme Ezh2 is critical for the maintenance of regulatory T cell identity after activation.
DuPage M; Chopra G; Quiros J; Rosenthal WL; Morar MM; Holohan D; Zhang R; Turka L; Marson A; Bluestone JA
Immunity; 2015 Feb; 42(2):227-238. PubMed ID: 25680271
[TBL] [Abstract][Full Text] [Related]
58. TNF activates a NF-kappaB-regulated cellular program in human CD45RA- regulatory T cells that modulates their suppressive function.
Nagar M; Jacob-Hirsch J; Vernitsky H; Berkun Y; Ben-Horin S; Amariglio N; Bank I; Kloog Y; Rechavi G; Goldstein I
J Immunol; 2010 Apr; 184(7):3570-81. PubMed ID: 20181891
[TBL] [Abstract][Full Text] [Related]
59. Treg cell therapy: How cell heterogeneity can make the difference.
Giganti G; Atif M; Mohseni Y; Mastronicola D; Grageda N; Povoleri GA; Miyara M; Scottà C
Eur J Immunol; 2021 Jan; 51(1):39-55. PubMed ID: 33275279
[TBL] [Abstract][Full Text] [Related]
60. Phenotypic and Functional Properties of Tumor-Infiltrating Regulatory T Cells.
Lee GR
Mediators Inflamm; 2017; 2017():5458178. PubMed ID: 29463952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
